VLG vs. CEL, EAH, PXS, STX, AGY, ANCR, BXP, APH, NCYT, and TRX
Should you be buying Venture Life Group stock or one of its competitors? The main competitors of Venture Life Group include Celadon Pharmaceuticals (CEL), ECO Animal Health Group (EAH), Provexis (PXS), Shield Therapeutics (STX), Allergy Therapeutics (AGY), Animalcare Group (ANCR), Beximco Pharmaceuticals (BXP), Alliance Pharma (APH), Novacyt (NCYT), and Tissue Regenix Group (TRX). These companies are all part of the "medical" sector.
Celadon Pharmaceuticals (LON:CEL) and Venture Life Group (LON:VLG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.
Venture Life Group has higher revenue and earnings than Celadon Pharmaceuticals. Venture Life Group is trading at a lower price-to-earnings ratio than Celadon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Venture Life Group had 9 more articles in the media than Celadon Pharmaceuticals. MarketBeat recorded 9 mentions for Venture Life Group and 0 mentions for Celadon Pharmaceuticals. Celadon Pharmaceuticals' average media sentiment score of 0.36 beat Venture Life Group's score of 0.00 indicating that Venture Life Group is being referred to more favorably in the news media.
5.5% of Celadon Pharmaceuticals shares are held by institutional investors. Comparatively, 52.9% of Venture Life Group shares are held by institutional investors. 66.1% of Celadon Pharmaceuticals shares are held by company insiders. Comparatively, 7.5% of Venture Life Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Celadon Pharmaceuticals presently has a consensus price target of GBX 222.50, suggesting a potential upside of 119.23%. Given Venture Life Group's higher possible upside, analysts plainly believe Celadon Pharmaceuticals is more favorable than Venture Life Group.
Venture Life Group received 152 more outperform votes than Celadon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Celadon Pharmaceuticals an outperform vote while only 72.90% of users gave Venture Life Group an outperform vote.
Celadon Pharmaceuticals has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, Venture Life Group has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.
Celadon Pharmaceuticals has a net margin of 0.00% compared to Celadon Pharmaceuticals' net margin of -1.56%. Celadon Pharmaceuticals' return on equity of -1.02% beat Venture Life Group's return on equity.
Summary
Venture Life Group beats Celadon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Venture Life Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VLG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Venture Life Group Competitors List
Related Companies and Tools
